5 days ago
1
Sundry Photography/iStock Editorial via Getty Images
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request seeking a label update for Winrevair, a treatment already approved in the U.S. for a lung disorder called pulmonary arterial hypertension (PAH).
English (US) ·